13F filer · CIK 1839435
Octagon Capital Advisors LP
NEW YORK, NY · filing since Q4 2020 · last filing Aug 14, 2026
Reported value
$1.1B
+$208.9M vs prior
Positions
27
New / sold out
5 / 7
Added / reduced
4 / 6
Turnover
14.8%
buys $149.1M · sells $170.4M
Top-10 weight
78.5%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Added | ABIVAX SA | +316,000 | +46.7% | +$42.1M |
| Added | DEFINIUM THERAPEUTICS INC | +510,000 | +20.9% | +$24.0M |
| New | ERASCA INCCALL | +1,255,000 | – | +$23.0M |
| New | SUMMIT THERAPEUTICS INC | +1,250,000 | – | +$18.2M |
| New | ADLAI NORTYE LTD | +934,716 | – | +$10.7M |
| Added | PHARVARIS N V | +291,721 | +176.8% | +$10.1M |
| New | FAETH THERAPEUTICS INC | +361,010 | – | +$9.0M |
| New | GYRE THERAPEUTICS INC | +954,416 | – | +$6.3M |
| Added | TAYSHA GENE THERAPIES INC | +833,333 | +9.4% | +$5.7M |
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | CENTESSA PHARMACEUTICALS PLC | -750,000 | -100.0% | $-29.8M |
| Sold out | KALVISTA PHARMACEUTICALS INC | -1,450,000 | -100.0% | $-29.2M |
| Sold out | TERNS PHARMACEUTICALS INC | -530,000 | -100.0% | $-27.9M |
| Reduced | TREVI THERAPEUTICS INC | -1,170,000 | -78.8% | $-21.8M |
| Reduced | KYMERA THERAPEUTICS INC | -115,000 | -27.1% | $-13.2M |
| Reduced | OCULAR THERAPEUTIX INC | -1,091,600 | -34.5% | $-10.7M |
| Reduced | DIANTHUS THERAPEUTICS INC | -105,000 | -5.4% | $-10.2M |
| Reduced | PRECISION BIOSCIENCES INC | -886,732 | -39.6% | $-7.0M |
| Sold out | BRIDGEBIO ONCOLOGY THERAPEUT | -719,000 | -100.0% | $-6.4M |
| Sold out | LEXEO THERAPEUTICS INC | -1,100,000 | -100.0% | $-6.3M |
3 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | DIANTHUS THERAPEUTICS INCCOM | 1,841,667 | $179.5M | 16.14% |
| 2 | DEFINIUM THERAPEUTICS INCCOM SHS | 2,950,000 | $138.8M | 12.47% |
| 3 | ABIVAX SASPONSORED ADS | 993,000 | $132.3M | 11.89% |
| 4 | COGENT BIOSCIENCES INCCOM | 2,350,000 | $90.9M | 8.17% |
| 5 | ALUMIS INCCOM | 2,830,700 | $79.7M | 7.16% |
| 6 | ARRIVENT BIOPHARMA INCCOM | 1,971,054 | $68.5M | 6.15% |
| 7 | TAYSHA GENE THERAPIES INCCOM SHS | 9,693,244 | $66.0M | 5.93% |
| 8 | BIOAGE LABS INCCOM | 1,748,000 | $42.8M | 3.85% |
| 9 | MIRUM PHARMACEUTICALS INCCOM | 338,900 | $39.7M | 3.57% |
| 10 | KYMERA THERAPEUTICS INCCOM | 310,000 | $35.5M | 3.20% |
17 more rows. Subscribe for $29/month to see every row, download the data and use the API.